Apotex Inc. is the first OTC drug firm to take a swing at landing a type of exclusivity the US Food and Drug Administration is granting to encourage development of more generic competition to brand name products.
US consumers currently don't have access to adequate private label and store brand competition for Aleve PM (naproxen sodium 220 mg/diphenhydramine hydrochloride 25 mg), the FDA decided on 22 August...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?